

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 18382

Title: Treatment of patients with tyrosine-methionine-aspartate-aspartate mutations

Reviewer's code: 03434086

Reviewer's country: China

Science editor: Jing Yu

Date sent for review: 2015-04-21 11:54

Date reviewed: 2015-05-26 10:23

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Point 1: This letter to editor try to clarify the usage of lamivudine in CHB patient that mentioned in article entitled by "Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B". Authors thought it was not appropriate to use lamivudine in YMDD mutation patients, actually, in China, The Diagnostic Standard from the Chinese National Program for Prevention and Treatment of Viral Hepatitis didn't suggest to do the mutation detection at the beginning of the treatment, so for most patients, doctors didn't know the mutation information at that time point, only after a period of treatment, if patients still in a high viral load, doctors try to prescribe the YMDD mutation detection to see if there any mutations, and then try to change the drug usage. But for the article mentioned above, the usage of lamivudine in patients that already known had YMDD mutation may have some ethics problems. Point 2: Some sentences need to be refined. Such as "Firstly, lamivudine use must be explained, although more potent drugs can be used for patients of very high viral load(mean HBV-DNA:6.67±2.47 Log 10 genome equivalents)." The logistic of this sentences is not clear.